Article Abstract

Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?

Authors: Maria A. Velez, Timothy F. Burns

Abstract

The immune checkpoint inhibitor pembrolizumab, has been shown to be efficacious and to have significant and durable antitumor activity in a subset of patients with advanced non-small cell lung cancer (NSCLC). Most notably in NSCLC with high expression of the programmed death ligand-1 (PD-L1). Similarly, there is abundant data to support the use of epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy in patients whose tumors harbor EGFR mutations (1).

Article Options

Download Citation